Key result
Baxdrostat offers an approved add-on for uncontrolled hypertension despite unproven long-term cardiovascular and renal outcomes.
Why the study?
Hard-to-control hypertension remains a major therapeutic problem, and mineralocorticoid receptor antagonists are limited by hyperkalemia, endocrine adverse effects, and tolerability concerns.
Does baxdrostat improve blood pressure control in adults with hard-to-control hypertension?
Does baxdrostat improve blood pressure control in adults with hard-to-control hypertension?
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“BaxHTN is a 'landmark study' that could redefine how clinicians think about people who do not respond sufficiently well to current drugs. It is clear that resistant hypertension […] could be usefully reconsidered so that it is not just accepted as the long-term consequence of poorly controlled 'essential hypertension'.”
“Aldosterone is a well-known driver of hypertension, but for decades scientists have struggled to block its production in a precise way. Baxdrostat is one of the first therapies to do so selectively. The near-10 mmHg placebo-adjusted reduction in SBP 'is exciting, as this level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure, and kidney disease.'”
“This Priority Review demonstrates our commitment to advancing baxdrostat as a potential first- and best-in-class aldosterone synthase inhibitor for the millions of people living with hard-to-control hypertension as quickly as possible. The substantial reduction in systolic blood pressure seen in the BaxHTN trial underscores baxdrostat's novel mechanism of action and its potential to bring innovation to a disease area that has seen limited progress in over two decades.”
Baxdrostat is a newly FDA-approved selective aldosterone synthase inhibitor that offers a novel add-on treatment option for adults with resistant or hard-to-control hypertension.
INTRODUCTION: Hard-to-control hypertension remains a major therapeutic problem despite wide availability of inexpensive antihypertensive drugs. Aldosterone dysregulation contributes to sodium retention, vascular injury, renal risk, and resistance to multidrug therapy, but mineralocorticoid receptor antagonists are limited by hyperkalemia, endocrine adverse effects, and tolerability concerns. AREAS COVERED: This Drug Evaluation reviews baxdrostat, an oral selective aldosterone synthase inhibitor approved by the U.S. Food and Drug Administration (FDA) on 18 May 2026 as add-on treatment for adults with hypertension inadequately controlled on other antihypertensive medicines. Regulatory status outside the United States may differ. The review covers mechanistic rationale, CYP11B2 selectivity, pharmacology, dosing, clinical efficacy, safety, monitoring, regulatory status, and comparative clinical positioning. A structured narrative search of PubMed/MEDLINE, ClinicalTrials.gov, and regulatory sources was conducted from database inception through 13 July 2026. EXPERT OPINION: Baxdrostat provides a mechanistically distinct approach to lowering aldosterone while comparatively sparing cortisol synthesis. Its current role is as a monitored add-on therapy for true uncontrolled or resistant hypertension after optimization of established treatment, particularly when an aldosterone-associated phenotype is suspected or mineralocorticoid receptor antagonists are not tolerated. Albuminuria findings remain hypothesis-generating. Long-term value depends on electrolyte safety, comparative effectiveness, and demonstration of cardiovascular and renal outcomes.
No takes yet. Share an insight, caveat, or question.
Aziz Ullah (2026) conducted a review in Hard-to-control hypertension. Baxdrostat was evaluated. Baxdrostat is a selective aldosterone synthase inhibitor approved as an add-on therapy for uncontrolled hypertension, though long-term cardiovascular and renal outcomes remain to be demonstrated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: